Loading clinical trials...
Loading clinical trials...
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Conditions
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202)
Long-Term Follow-Up of Patients who Received Placebo
Locations
14
United States
Arizona Research Center
Phoenix, Arizona, United States
Clinical Trials, Inc.
Little Rock, Arkansas, United States
Northern California Research
Sacramento, California, United States
Center for Clinical Research
San Francisco, California, United States
Neurological Research Institute
Santa Monica, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Start Date
February 4, 2019
Primary Completion Date
July 24, 2019
Completion Date
July 24, 2019
Last Updated
October 9, 2025
NCT06524284
NCT04857957
NCT03755934
NCT05620225
NCT06383702
NCT05993871
Lead Sponsor
Helixmith Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions